| # | Title | Journal | Year | Citations |
|---|
| 1 | Hematological Malignancies and Pregnancy: A Final Report of 84 Children Who Received Chemotherapy In Utero | Clinical Lymphoma and Myeloma | 2001 | 375 |
| 2 | An Update of the Epidemiology of Non-Hodgkin's Lymphoma | Clinical Lymphoma and Myeloma | 2003 | 152 |
| 3 | Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients | Clinical Lymphoma and Myeloma | 2002 | 148 |
| 4 | Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chain–Associated (AL) Amyloidosis | Clinical Lymphoma and Myeloma | 2003 | 137 |
| 5 | The Impact of Age on Delivered Dose Intensity and Hospitalizations for Febrile Neutropenia in Patients with Intermediate-Grade Non-Hodgkin's Lymphoma Receiving Initial CHOP Chemotherapy: A Risk Factor Analysis | Clinical Lymphoma and Myeloma | 2001 | 132 |
| 6 | DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma | Clinical Lymphoma and Myeloma | 2000 | 130 |
| 7 | Biological Correlates of Acute Hypersensitivity Events with DAB389IL-2 (Denileukin Diftitox, ONTAK®) in Cutaneous T-Cell Lymphoma: Decreased Frequency and Severity with Steroid Premedication | Clinical Lymphoma and Myeloma | 2001 | 121 |
| 8 | Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma | Clinical Lymphoma and Myeloma | 2004 | 117 |
| 9 | Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival | Clinical Lymphoma and Myeloma | 2003 | 101 |
| 10 | Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®) | Clinical Lymphoma and Myeloma | 2002 | 95 |
| 11 | Management Guidelines for Use of Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia | Clinical Lymphoma and Myeloma | 2004 | 91 |
| 12 | Primary Adrenal Lymphoma | Clinical Lymphoma and Myeloma | 2003 | 87 |
| 13 | Frequent Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography on the Staging and Management of Patients with Indolent Non-Hodgkin's Lymphoma | Clinical Lymphoma and Myeloma | 2003 | 78 |
| 14 | Primary Large-Cell Non-Hodgkin's Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors | Clinical Lymphoma and Myeloma | 2001 | 72 |
| 15 | Extended Rituximab Therapy for Previously Untreated Patients with Waldenström's Macroglobulinemia | Clinical Lymphoma and Myeloma | 2002 | 71 |
| 16 | CD5, CD10, and CD23 Expression in Waldenström's Macroglobulinemia | Clinical Lymphoma and Myeloma | 2005 | 71 |
| 17 | Proteasome Inhibitors in the Treatment of B-Cell Malignancies | Clinical Lymphoma and Myeloma | 2002 | 65 |
| 18 | Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia | Clinical Lymphoma and Myeloma | 2002 | 65 |
| 19 | Stage I-IIE Primary Non-Hodgkin's Lymphoma of the Testis: Results of a Prospective Trial by the GOELAMS Study Group | Clinical Lymphoma and Myeloma | 2002 | 58 |
| 20 | Etiology, Diagnosis, and Treatment Recommendations for Central Hypothyroidism Associated with Bexarotene Therapy for Cutaneous T-Cell Lymphoma | Clinical Lymphoma and Myeloma | 2003 | 58 |
| 21 | Autoantibody Activity in Waldenström's Macroglobulinemia | Clinical Lymphoma and Myeloma | 2005 | 58 |
| 22 | Primary Ocular Lymphoma: Clinical Features, Diagnosis, and Treatment | Clinical Lymphoma and Myeloma | 2003 | 57 |
| 23 | Cutaneous Manifestations of Lymphoma: A Clinical Guide Based on the WHO Classification | Clinical Lymphoma and Myeloma | 2001 | 56 |
| 24 | Clinicopathological Correlates of IgM Paraproteinemias | Clinical Lymphoma and Myeloma | 2000 | 55 |
| 25 | CHOP plus Rituximab Therapy in Waldenström's Macroglobulinemia | Clinical Lymphoma and Myeloma | 2005 | 55 |
| 26 | Paraneoplastic Manifestations of Lymphoma | Clinical Lymphoma and Myeloma | 2004 | 54 |
| 27 | DAB389IL-2 (Denileukin Diftitox, ONTAK): A New Fusion Protein Technology | Clinical Lymphoma and Myeloma | 2000 | 51 |
| 28 | Diagnosis and Management of Primary Nasal Lymphoma of T-Cell or NK-Cell Origin | Clinical Lymphoma and Myeloma | 2000 | 50 |
| 29 | Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity? | Clinical Lymphoma and Myeloma | 2005 | 50 |
| 30 | Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma | Clinical Lymphoma and Myeloma | 2000 | 49 |
| 31 | Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin's Lymphoma | Clinical Lymphoma and Myeloma | 2004 | 47 |
| 32 | Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma | Clinical Lymphoma and Myeloma | 2005 | 47 |
| 33 | Acquired Immunodeficiency Syndrome–Related Lymphoma in the Era of Highly Active Antiretroviral Therapy | Clinical Lymphoma and Myeloma | 2003 | 44 |
| 34 | Non-Hodgkin's Lymphoma Affecting the Testis: Is It Curable with Doxorubicin-Based Therapy? | Clinical Lymphoma and Myeloma | 2001 | 42 |
| 35 | Enhanced Marrow [18F]Fluorodeoxyglucose Uptake Related to Myeloid Hyperplasia in Hodgkin's Lymphoma Can Simulate Lymphoma Involvement in Marrow | Clinical Lymphoma and Myeloma | 2004 | 42 |
| 36 | Non-Hodgkin's Lymphoma of the Breast: A Report of 19 Cases and a Review of the Literature | Clinical Lymphoma and Myeloma | 2005 | 42 |
| 37 | Management of Hepatic Sinusoidal Obstruction Syndrome Following Treatment with Gemtuzumab Ozogamicin (Mylotarg®) | Clinical Lymphoma and Myeloma | 2002 | 40 |
| 38 | The Implications of Anemia in Multiple Myeloma | Clinical Lymphoma and Myeloma | 2003 | 40 |
| 39 | CpG Oligodeoxynucleotides Enhance Monoclonal Antibody Therapy of a Murine Lymphoma | Clinical Lymphoma and Myeloma | 2000 | 39 |
| 40 | Are Radiometal-Labeled Antibodies Better Than Iodine-131–Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67–, Iodine-131–, and Yttrium-90–Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma | Clinical Lymphoma and Myeloma | 2000 | 39 |
| 41 | Pilot Study of Fixed-Infusion Rate Gemcitabine with Cisplatinand Dexamethasone in Patients with Relapsed or Refractory Lymphoma | Clinical Lymphoma and Myeloma | 2004 | 38 |
| 42 | CD33 as a Target for Selective Ablation of Acute Myeloid Leukemia | Clinical Lymphoma and Myeloma | 2002 | 37 |
| 43 | Nongastric Mucosa-Associated Lymphoid Tissue Lymphomas | Clinical Lymphoma and Myeloma | 2003 | 37 |
| 44 | First-Line Treatment with Brief-Duration Chemotherapy Plus Rituximab in Elderly Patients with Intermediate-Grade Non-Hodgkin's Lymphoma: Phase II Trial | Clinical Lymphoma and Myeloma | 2003 | 37 |
| 45 | Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature | Clinical Lymphoma and Myeloma | 2004 | 37 |
| 46 | Challenges in the Management of Burkitt's Lymphoma | Clinical Lymphoma and Myeloma | 2002 | 36 |
| 47 | Recombinant Urate Oxidase for Prevention of Hyperuricemia and Tumor Lysis Syndrome in Lymphoid Malignancies | Clinical Lymphoma and Myeloma | 2003 | 36 |
| 48 | Predictive Factors for Response to Rituximab in Waldenström's Macroglobulinemia | Clinical Lymphoma and Myeloma | 2005 | 36 |
| 49 | Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia | Clinical Lymphoma and Myeloma | 2002 | 35 |
| 50 | Hepatitis C Virus Infection and B-Cell Non-Hodgkin's Lymphomas: More Than a Simple Association | Clinical Lymphoma and Myeloma | 2002 | 34 |
